Stifel Financial
RNAM

Stifel Financial’s Avidity Biosciences RNAM Stock Holding History

Stifel Financial’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,936
Closed -$869K – 3692
2025
Q3 		$869K Buy
19,936
+5,220
+35% +$211K ﹤0.01% 2482
2025
Q2 		$418K Buy
14,716
+88
+0.6% +$2.62K ﹤0.01% 2868
2025
Q1 		$432K Buy
14,628
+7,679
+111% +$239K ﹤0.01% 2780
2024
Q4 		$202K Sell
6,949
-1,063
-13% -$44.4K ﹤0.01% 3162
2024
Q3 		$368K Buy
+8,012
New +$348K ﹤0.01% 2859

Other funds holding RNAM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Stifel Financial's RNAM Position: Q4 2025 in Review

Stifel Financial sold out of Avidity Biosciences (RNAM) in Q4 2025, closing a stake of 19,936 shares — an estimated $869K sold.

Stifel Financial first reported a position in RNAM in Q3 2024 and held it in 5 quarters. The position peaked at $869K in Q3 2025. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

  • Stifel Financial reported no remaining Avidity Biosciences position as of Q4 2025 after selling out during the quarter.
  • Stifel Financial sold 19,936 Avidity Biosciences shares in Q4 2025, an estimated $869K.
  • Stifel Financial first reported a position in Avidity Biosciences in Q3 2024 and held it in 5 quarters.
  • Stifel Financial's Avidity Biosciences position peaked at $869K in Q3 2025.
  • 343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on Stifel Financial's 13F filing for Q4 2025, filed 13 Feb 2026.